ASND
Ascendis Pharma A/S
There isn't enough reported data to score ASND yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ASND Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Under pressure | |
| Strong |
ASND's profitability and balance sheet are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its revenue.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ASND PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $267 | — |
| Cheap | 22x | $313 | +17% |
| Fair | 27x | $388 | +45% |
| Expensive | 29x | $428 | +60% |
Historical ranges are pointers, not guarantees.
ASND has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ASND Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ASND, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ASND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $14.54 | +$18.78 |
| Q4 2025 | -$4.18 | +$3.07 |
| Q3 2025 | -$4.24 | +$4.05 |
| Q2 2025 | -$5.04 | +$4.54 |
| Q1 2025 | -$6.45 | +$3.41 |
| Q4 2024 | -$7.25 | +$2.25 |
| Q3 2024 | -$8.29 | +$3.61 |
| Q2 2024 | -$9.58 | +$2.49 |
ASND has the stronger earnings trend. Trailing diluted EPS is up 125% for ASND versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ASND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +347% |
| Q4 2025 | $274.9M | +42% |
| Q3 2025 | $237.3M | +269% |
| Q2 2025 | $175.6M | +339% |
| Q1 2025 | $112.1M | +5.3% |
| Q4 2024 | $193.2M | +26% |
| Q3 2024 | $64.2M | +20% |
| Q2 2024 | $40M | -24% |
ASND has the stronger quarterly revenue trend. Revenue is up 847% for ASND versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +142 points |
| Q4 2025 | 4% | +3.8 points |
| Q3 2025 | 5.2% | +172 points |
| Q2 2025 | -34% | +337 points |
| Q1 2025 | -103% | -52 points |
| Q4 2024 | 0.2% | +27 points |
| Q3 2024 | -167% | +113 points |
| Q2 2024 | -370% | -73 points |
ASND has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ASND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$62.9M | +$76.8M |
| Q2 2024 | -$68.5M | +$102.1M |
| Q1 2024 | -$113.1M | +$51.5M |
| Q4 2023 | -$47.1M | +$114.5M |
| Q3 2023 | -$139.6M | -$26.3M |
| Q2 2023 | -$170.6M | -$28.3M |
| Q1 2023 | -$164.6M | -$15M |
| Q4 2022 | -$161.6M | -$19.3M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with ASND at up 36%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ASND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +6.2M shares |
| 1 year | +11% | +6.8M shares |
| 3 years | +19% | +10.7M shares |
| 5 years | +24% | +13M shares |
| Available history | +42% | +19.6M shares |
ASND has 67M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $173.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $19.3M |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $2,222 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ASND on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ASND Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
ASND has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ASND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 73.4 | Neutral |
ASND's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ASND PE vs Healthcare Sector
| Metric | ASND | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 4 | 29 | 25 pts below |
ASND has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ASND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $240.8 | 11% above |
| 20 week MA | $250.3 | 6.7% above |
| 50 week MA | $235.2 | 14% above |
| 100 week MA | $202.9 | 32% above |
| 200 week MA | $160.1 | 67% above |
ASND is in an uptrend: it's above all five of its weekly moving averages, and 67% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ASND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.1 | $170.9 | +27% |
| 2021 | $170.9 | $139.3 | -18% |
| 2022 | $139.3 | $119.1 | -15% |
| 2023 | $119.1 | $126.0 | +5.8% |
| 2024 | $126.0 | $137.5 | +9.2% |
| 2025 | $137.5 | $209.0 | +52% |
| 2026 YTD | $209.0 | $267.1 | +28% |
ASND has finished higher in four of the last six years. It's up 28% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ASND on returns for 2026, with the stronger performance.